295 related articles for article (PubMed ID: 22069557)
21. Six-year dialysis freedom in end-stage renal disease.
Al Mosawi AJ
Clin Exp Nephrol; 2009 Oct; 13(5):494-500. PubMed ID: 19479191
[TBL] [Abstract][Full Text] [Related]
22. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.
Mydlík M; Derzsiová K
Kidney Int Suppl; 2001 Feb; 78():S304-7. PubMed ID: 11169031
[TBL] [Abstract][Full Text] [Related]
23. Advanced glycation endproducts (AGEs) as uremic toxins.
Schwenger V; Zeier M; Henle T; Ritz E
Nahrung; 2001 Jun; 45(3):172-6. PubMed ID: 11455783
[TBL] [Abstract][Full Text] [Related]
24. Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute?
Sebeková K; Wagner Z; Schupp N; Boor P
Kidney Blood Press Res; 2007; 30(1):56-66. PubMed ID: 17261927
[TBL] [Abstract][Full Text] [Related]
25. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients.
Piroddi M; Depunzio I; Calabrese V; Mancuso C; Aisa CM; Binaglia L; Minelli A; Butterfield AD; Galli F
Amino Acids; 2007; 32(4):573-92. PubMed ID: 17356806
[TBL] [Abstract][Full Text] [Related]
26. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors.
Schupp N; Schinzel R; Heidland A; Stopper H
Ann N Y Acad Sci; 2005 Jun; 1043():685-95. PubMed ID: 16037294
[TBL] [Abstract][Full Text] [Related]
27. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
Dierkes J; Domröse U; Ambrosch A; Bosselmann HP; Neumann KH; Luley C
Clin Nephrol; 1999 Feb; 51(2):108-15. PubMed ID: 10069646
[TBL] [Abstract][Full Text] [Related]
28. The Impact of CKD on Uremic Toxins and Gut Microbiota.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
[TBL] [Abstract][Full Text] [Related]
29. Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients.
Stopper H; Boullay F; Heidland A; Vienken J; Bahner U
Am J Kidney Dis; 2001 Aug; 38(2):296-301. PubMed ID: 11479155
[TBL] [Abstract][Full Text] [Related]
30. Homocysteine exerts genotoxic and antioxidative effects in vitro.
Fink K; Brink A; Vienken J; Heidland A; Stopper H
Toxicol In Vitro; 2007 Dec; 21(8):1402-8. PubMed ID: 17590309
[TBL] [Abstract][Full Text] [Related]
31. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
32. The role of peritoneal dialysis in renal replacement therapy: an update on medical aspects.
Yao Q; Wang X; Chung SH; Pecoits-Filho R; Stenvinkel P; Wang T; Heimbürger O; Lindholm B
Panminerva Med; 2005 Mar; 47(1):19-30. PubMed ID: 15985974
[TBL] [Abstract][Full Text] [Related]
33. Cholecalciferol Supplementation Did Not Change Interleukin-7 and B cell-Activating Factor Levels and CD95 Expression in B lymphocytes in Patients on Dialysis: A Randomized Pilot-Controlled Trial.
de Carvalho JTG; Schneider M; Cuppari L; Grabulosa CC; Cendoroglo M; Dalboni MA
J Ren Nutr; 2019 Sep; 29(5):454-461. PubMed ID: 30686751
[TBL] [Abstract][Full Text] [Related]
34. Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis.
Thongprayoon C; Kaewput W; Hatch ST; Bathini T; Sharma K; Wijarnpreecha K; Ungprasert P; D'Costa M; Mao MA; Cheungpasitporn W
Dig Dis Sci; 2019 Feb; 64(2):469-479. PubMed ID: 30099652
[TBL] [Abstract][Full Text] [Related]
35. Vitamin replacement therapy in renal failure patients.
Makoff R
Miner Electrolyte Metab; 1999; 25(4-6):349-51. PubMed ID: 10681665
[TBL] [Abstract][Full Text] [Related]
36. Polymeric protein-polyamine conjugates: a new class of uremic toxins affecting erythropoiesis.
Galli F; Beninati S; Benedetti S; Lentini A; Canestrari F; Tabilio A; Buoncristiani U
Kidney Int Suppl; 2001 Feb; 78():S73-6. PubMed ID: 11168987
[TBL] [Abstract][Full Text] [Related]
37. Acacia gum supplementation of a low-protein diet in children with end-stage renal disease.
Al-Mosawi AJ
Pediatr Nephrol; 2004 Oct; 19(10):1156-9. PubMed ID: 15293039
[TBL] [Abstract][Full Text] [Related]
38. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.
Arsov S; Graaff R; van Oeveren W; Stegmayr B; Sikole A; Rakhorst G; Smit AJ
Clin Chem Lab Med; 2014 Jan; 52(1):11-20. PubMed ID: 23612551
[TBL] [Abstract][Full Text] [Related]
39. Renal versus continuous versus intermittent therapies for removal of uremic toxins.
Clark WR; Henderson LW
Kidney Int Suppl; 2001 Feb; 78():S298-303. PubMed ID: 11169030
[TBL] [Abstract][Full Text] [Related]
40. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure.
Satoh M; Hayashi H; Watanabe M; Ueda K; Yamato H; Yoshioka T; Motojima M
Nephron Exp Nephrol; 2003; 95(3):e111-8. PubMed ID: 14646363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
